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ABSTRACT – Pneumonia is a leading cause of loss to the sheep and cattle industry throughout the
world. Mannheimia (Pasteurella) haemolytica is one of the most important respiratory pathogens of
domestic ruminants and causes serious outbreaks of acute pneumonia in neonatal, weaned and growing
lambs, calves, and goats. M. haemolytica is also an important cause of pneumonia in adult animals.
Transportation, viral infections with agents such as infectious bovine rhinotracheitis virus,
parainfluenza-3 virus or bovine respiratory syncytial virus, overcrowding, housing of neonates and
weaned animals together and other stressful conditions predispose animals to M. haemolytica infection
[1, 2]. This review assimilates some of the findings key to cellular and molecular responses of the lung
from a pathologist's perspective. It includes some of what is known and underscores areas that are not
fully understood. © 2000 Éditions scientifiques et médicales Elsevier SAS
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1. Innate immunity
Mannheimia haemolytica colonizes the mucosa of the
upper respiratory tract and nasopharynx. By mechanisms
poorly understood, M. haemolytica breeches the innate
mucosal defense, including the mucociliary apparatus
and antimicrobial factors to establish infection in the lung.
Acute pulmonary infections caused by M. haemolytica are
characterized by a peracute to acute fibrinosuppurative
and necrotizing inflammatory response. Within hours after
infection, the lung bronchi, bronchioles and alveoli con-
tain dense infiltrates of neutrophils, fibrin, seroproteina-
ceous fluid and blood (figure 1). The exudate is associated
with extensive parenchymal necrosis that is caused by M.
haemolytica products such as leukotoxin, lipopolysaccha-
ride and polysaccharide and also inflammatory factors
released by neutrophils and other cells of the acute inflam-
matory process. The contribution of the neutrophil to
parenchymal damage in bovine pulmonary pasteurellosis
was demonstrated by a study in which calves depleted of
neutrophils and inoculated with M. haemolytica had
reduced parenchymal damage when compared with
calves with normal levels of neutrophils [3]. Neutrophil
constituents that potentially contribute to the tissue dam-
age include enzymes such as elastase and acid hydrolases,
oxidative radicals, cytokines and chemokines. The
neutrophil-mediated damage is likely exacerbated by
serum factors such as complement. Although neutrophil
infiltration during M. haemolytica pneumonia is necessary
for resistance to infection, the response is typically exten-
sive and excessive. Methods and therapies to regulate the
acute inflammatory response may reduce the overall sever-
ity of M. haemolytica pneumonia.
The activity of the mucociliary apparatus reduces the
ability of microbes to adhere and proliferate within the
airways of the respiratory tract. Within the secreted muci-
nous and serous fluids of the airways are factors that
inhibit microbial activity. These include lactoferrin,
lysozyme, surfactant proteins, phospholipase A2, secre-
tory leukoprotease inhibitor, peroxidases, bactericidal-
permeability-inducing factor, lysozyme, serprocidins,
cathelicidins, defensins and anionic peptides [4]. It is
becoming increasingly apparent that mammalian bron-
chial and bronchiolar epithelial cells are responsive to
products of Gram-negative bacteria, including M.
haemolytica. Shortly after M. haemolytica infection, epi-
thelial cells of these airways have increased mRNA tran-
scription of intercellular adhesion molecule-1 (ICAM-1)
[5]. ICAM-1 likely serves as a ligand for inflammatory cells
in the process of transmigration into the airway lumen. As
indicated, alveolar macrophage and neutrophil infiltration
into alveoli protects against bacterial infection, if the infil-
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trative process is not excessive. Respiratory epithelial cell
production of at least two antimicrobial peptides is
increased during M. haemolytica pneumonia in cattle.
These are the -defensins termed tracheal antimicrobial
peptide (TAP) [6] and lingual antimicrobial peptide (LAP)
[7]. Both TAP and LAP have potent antibacterial activity;
TAP also incites the degranulation of mast cells. The
inducible form of nitric oxide synthtase is produced at a
high level in non-inflamed bronchial and bronchiolar
epithelial cells, but the level of its production by these
cells decreases shortly after M. haemolytica infection [8].
There are a number of other epithelial cells in lung that
likely also have a role in M. haemolytica pneumonia.
Goblet cells and submucosal gland cells contribute secre-
tion products to mucociliary layer and the inflammatory
response. Epithelial cells (Clara cells) expressing mixed
function oxidases for the detoxification of noxious com-
pounds may initiate localized areas of inflammation; how-
ever, little is known of the responses of such specialized
cells during M. haemolytica pneumonia.
The ruminant lung has anatomic features which limit its
ability to resolve pneumonic episodes. Lungs of ruminants
have relatively few pores of Kohn between alveolar units,
which reduces the degree of collateral ventilation. This
prevents the amount of air that can be delivered from
alveolar units with adequate ventilation to those that are
partially occluded by exudate or edema fluid. The rumi-
nant lung has little interdependence due to extensive
interlobular septa, which also reduces alveolar expansion.
These features make it difficult for alveolar inflation during
pneumonic episodes and reduce the capacity to expel
alveolar exudate. Thus, a viable innate immune system
consisting of an intact airway epithelium and functional
muciliary apparatus is essential for preventing initial infec-
tion of the lower respiratory tract.
1.1. Antimicrobial factors and peptides
Free radicals such as superoxide and hydroxy radical
are produced by activated macrophages and neutrophils
during M. haemolytica infection and cause oxidative dam-
age of phospholipid membranes (conjugated diene forma-
tion), DNA, RNA, glycoconjugates, and proteins of paren-
chymal cells. The free radicals are also active against
extracellular and internalized M. haemolytica. Eukaryotic
cells protect their own membranes, cytosol and organelles
from free radical damage by nonenzymatic (vitamin A, E,
C) and enzymatic (superoxide dismutase) mechanisms. M.
haemolytica organisms may be able to resist at least a
certain level of free radical damage, since serotypes A1
and A2 produce superoxide dismutase [2, 9].
Recent work increasingly indicates that respiratory
mucosal epithelia and leukocytes of ruminants produce
antimicrobial peptides, including -defensins, anionic
peptides, and cathelicidins, all of which have potent micro-
cidal activity [4, 6, 7, 10, 11, 12, 13]. In the ruminant lung,
-defensins of cattle include TAP and LAP and of sheep
Figure 1. Inflammatory response in the alveoli of lung from a calf inoculated intrabronchially with M. haemolytica via fiberoptic
bronchscope. Epithelial cells lining alveolar lumens (type I cells) are stained (red) by immunohistochemistry with an antibody to human
cytokeratin (Clone MNF116, specific for CKs 5, 6, 8, 17, 19; Dako Corporation) and alveolar macrophages are stained (brown) with an
antibody to CD68 (Clone EBM11, Dako Corporation). Alveolar lumens also contain neutrophils, fibrin and seroproteinaceous fluid. Tissues
are counterstained with hematoxlyn.
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include sheep -defensin 1 (SBD-1; SBD-2 is expressed in
ovine ileum). Anionic peptide is also produced by epithe-
lial cells of the lung of both cattle and sheep. TAP, LAP and
probably SBD-1 expression can be enhanced by inflam-
matory stimuli; however anionic peptide appears to be
constituitively expressed. Although cathelicidin produc-
tion occurs in ruminant leukocytes and in human lung and
skin, its production by respiratory mucosa in sheep and
cattle has not yet been determined. The surfactant-
associated proteins A and D are members of a family of
collageneous host defense lectins, designated collectins.
The collectins bind to carbohydrate and lipid moieties
expressed by microorganisms and organic particles, and
may modulate leukocyte activity [14]. The production of
antimicrobial peptides and collectins in utero, by the
neonate, or in the adult, remain poorly understood in
cattle, sheep and other ruminants.
2. Inflammatory process initiated by
M. haemolytica
Although it is known that M. haemolytica colonizes the
upper respiratory tract of otherwise healthy ruminants, in
some animals M. haemolytica causes severe pneumonia
and death. The understanding of the mechanisms by which
the bacteria colonize and eventually cause pneumonia is
limited. M. haemolytica is a Gram-negative organism with
a prominent polysaccharide capsule and resides in the
mucus and in the secretion products of the ventral nasal
meatus, sinuses and in tonsil. M. haemolytica contains a
capsule composed of →3)-B-N-acetylaminomannuronic-
(1→4)-B-N-acetylmannosamine-(1→. This capsular
polysaccharide may be involved in an adhesin-receptor
interaction, with surfactant mediating the attachment of
M. haemolytica in the alveolus (figure 2). Alveolar epithe-
lial cells contain carbohydrate on the surface, which binds
a lectin in the pulmonary surfactant. This lectin, in human
and canine pulmonary surfactants, is a calcium-dependent,
mannose-binding protein of 28 000 to 36 000 Da. M.
haemolytica in the alveolus may attach to this surfactant
layer by the lectin reaction of its capsular polysaccharide.
The affinity of some lectins to the glycocalyx of M.
haemolytica can change when the bacteria are grown in
chambers or exposed to serum [15], which suggests that
the bacteria may alter glycoconjugate expression in vivo.
These changes may affect colonization and invasiveness
through bacterial glycoconjugates binding to receptors
expressed by mucosal cells. Glycoconjugate/receptor
binding may be further enhanced through the enzymatic
activity of neuraminidase, which is produced by M.
haemolytica in increased amounts during times of stress in
the host [1, 16]. The increased neuraminidase is accom-
panied by increased replication of M. haemolytica [1, 16].
The inflammatory response that occurs during M.
haemolytica pneumonia can be initiated by live M.
haemolytica, heat-killed M. haemolytica, M. haemolytica
lipopolysaccharide (LPS), M. haemolytica capsular
polysaccharide, and M. haemolytica leukotoxin (LKT) [1,
2, 17, 18]. During infection with live, whole cell M.
haemolytica, LPS, polysaccharide and LKT are released
into the intraalveolar exudate [18, 19, 20]. LPS is also
taken up by neutrophils, and polysaccharide localizes in
the alveolus and alveolar macrophages [18, 19, 20]. The
inflammatory response is mediated by several cell types,
including the vascular endothelium, pulmonary alveolar
and intravascular macrophages (PAMs and PIMs), neutro-
phils, mast cells, nerve fibers, lymphocytes, and airway
epithelial cells (table I). M. haemolytica infection induces
release of IL-1, TNF-α and IL-8 by lung tissue [21, 22] and
initiates a profound procoagulant state resulting in exten-
sive fibrin polymerization [23]. Other inflammtory media-
tors released by bovine lung in response to M. haemolytica
products (LPS and LKT) include leukotriene B4, histamine
and prostaglandin E2 [24, 25]. A wide-spreading cascade
of other cytokines and inflammatory mediators are likely
released during acute M. haemolytica pneumonia and
would likely include platelet-activating factor; however,
only a small subset of these factors has been characterized
in experimental conditions. Recent work suggests that
there may be a specialized pathway of LPS binding to the
LPS receptor, CD14, in the lung [26]. The study demon-
strated that human surfactant protein A binds rough LPS of
Escherichia coli and mediates adherence of the rough LPS
to both the membrane and soluble forms of CD14 [26].
Another study has shown that several hours (8 to 30 hours)
after mice have been exposed to LPS a 'late mediator,' [27]
HMG-1, is released. Increased levels of HMG-1 were
associated with lethality. Activities of mediators such as
human surfactant protein A and HMG-1 have not been
investigated in M. haemolytica pneumonia; however, M.
haemolytica LPS clearly has a prominent role in initiating
the inflammatory response in ruminants. There is also
likely a transition from acute pro-inflammatory cytokines
to regulatory cytokines such as IL-12 and transforming
growth factor beta (TGF-) that occurs some time after the
Figure 2. Electron micrograph of an M. haemolytica bacterium
closely associated to a pulmonary epithelial cell (type I) that lines
the alveolar wall. The epithelial cell has an undulated membrane
in the region of the bacteria. The bacteria is labeled with colloidal
gold particles linked to an anti-M. haemolytica antibody. Lead
citrate and uranyl acetate stain, × 28 000.
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acute inflammatory response subsides, but very little is
known about the molecular aspects of the progressive
nature of M. haemolytica pneumonia.
RTX toxins such as M. haemolytica LKT are not com-
monly produced by respiratory tract pathogens [28]. LKT,
as it name indicates, can be toxic to ruminant leukocytes,
and the dense infiltrates of neutrophils and other leuko-
cytes which enter sites of lung infected with M.
haemolytica are immediately vulnerable to the LKT activ-
ity. LKT binds the 2 integrin receptors of ruminant leuko-
cytes and platelets [29, 30]. This binding induces apopto-
sis, formation of pore-like structures in the plasma
membrane [31], activation of phospholipase A2 in a
calcium-dependent manner [32], and increased LTB4 pro-
duction in neutrophils [33]. The apoptotic process can be
exacerbated by tilmicosin [33] and the selectin inhibitor
TBC1269 [8]. Experimentally, LKT activity is enhanced by
polymerized F-actin and it is likely that polymerized F-actin
is present in the lungs of cattle with M. haemolytica
pneumonia, since whole cell M. haemolytica can convert
extracellular G-actin (released from dead cells) to poly-
merized F-actin [34]. M. haemolytica LPS also enhances
LKT activity through the formation of an LPS-LKT complex
[35]. Although LKT is toxic to leukocytes, including mac-
rophages, subcytotoxic levels of LKT enhance alveolar
macrophage production of NF-kappa beta, elevate cal-
cium [36] and induce the production of TNF-α and IL-1.
3. Acute and subacute inflammatory
response
3.1. Vasculature
Although extensive intravascular coagulation does not
occur in acute pasteurellosis, initiation of the coagulation
cascade is evidenced by polymerization of fibrin admixed
with pulmonary intravascular macrophges within capillar-
ies and sub- and intraendothelial locations [19]. M.
haemolytica LPS and IL-1 induce tissue factor production
and procoagulant activity by endothelial cells [37, 38]. A
monoclonal antibody to tissue factor prevents fibrin for-
mation, platelet degeneration and severity of lung lesions
in an experimental model in calves [38]. M. haemolytica
infection also influences endothelial cell activation, since
ICAM-1 mRNA is expressed in increased amounts as soon
as six hours following experimental deposition of M.
haemolytica in the lung [5]. This leads to increased leuko-
cyte adherence and infiltration. LKT has no direct effect on
vascular endothelial cells; however, LKT and LPS can
Table I. Cells of the respiratory tract and key roles of these cells in responsiveness to M. haemolytica infection in
ruminant lung.
Cell type Location Function Molecular expression
Squamous cells Tonsil, upper respiratory
tract
Resist colonization Surface glyconjugalates
Ciliated epithelial cells Upper respiratory tract Mucociliary activity, resist
colonization, adhesion molecule
activity
ICAM-1, AMP*
Submucosal gland cells Upper respiratory tract,
bronchi
Mucinous and serous secretions Possible AMP activity
Type II cells Bronchi/bronchioles Surfactant, surfactant proteins,
reepithelization after type I cell injury
SP A-D [collectins]
(opsonization, anti-microbial
activity, LPS binding), AMP
Clara cells Bronchioles Detoxification of toxins Mixed function oxidases
Type I cells Alveoli Air-blood barrier (gaseous exchange) Surfactant
Extracellular matrix Alveoli, pleura, interlobular
septa
Structural support, migration of
leukocytes
Collagen, tenascin,
vitronectin, fibronectin
Nerve fibers Interstitial tissue Tone of vessels, airways; regulation
of mast cell activity
Substance P
Mast cells Interstitial tissue Acute inflammation, construction of
vessels, airways
Histamine, protease
Blood vessels/lymph Interstitial area, alveolar
septa
Gaseous exchange, inflammation,
coagulation
Adhesion molecules, tissue
factor, cytokines, von
willebrand factor for platelet
adherence
Neutrophilis Circulation Acute inflammatory response Oxidative radicals, enzymes,
AMP
Platelets Circulation Hemostasis Platelet activating factor,
fibrin cross-links
Alveolar macrophage Alveolus Phagocytosis of debris, regulation of
acute and chronic inflammation,
antigen presentation
Cytokines, MHC II + pro-
inflammatory mediators
Intravascular
macrophage
Alveolar capillaries Internalization of hematogenous
substances
Cytokines, pro-inflammatory
mediators
*AMP = antimicrobial peptide, including TAP, LAP, anionic peptide, cathelcidins, collectins.
Review Ackermann and Brogden
1082 Microbes and Infection
2000, 1079-1088
stimulate leukocyte activity, and the soluble products
released by alveolar macrophages cause endothelial cell
injury [39]. Little is known of the effects of M. haemolytica
products on vascular tone, smooth muscle contractility,
nitric oxide-induced vasodilation or endothelin-induced
vasoconstriction.
The lymphatic vessels of the pulmonary interlobular
septae become markedly distended and filled with poly-
merized fibrin and neutrophils during M. haemolytica
pneumonia. Areas of necrosis often track along these
regions and extend across interlobular septae into the
adjacent lobules. Despite this characteristic and consis-
tent finding, little is known of lymphatic drainage alter-
ations or lymphatic endothelial cells' activity during M.
haemolytica pneumonia. It is a location where many
aspects of the infectious process aggregate and this
includes intra- and extracellular bacteria, neutrophils,
macrophages, fibrin, and seroproteinaceous fluid.
Enhanced delivery of antibiotics or other therapeutics to
this location may be beneficial in improving the drainage
of exudate from the lung.
3.2. Neutrophils and the acute inflammatory response
Neutrophil infiltration during M. haemolytica pneumo-
nia is associated with alveolar epithelial cell damage and
necrosis. The importance of neutrophil-mediated damage
in the pathogenesis of M. haemolytica pneumonia is under-
scored by the fact that neutrophil depletion ameliorates
the tissue damage and vascular leakage of protein [3].
Neutrophils mediate damage by release of enzymes such
as elastase, oxidative radicals and cytokines, and these
substances incite membrane damage, the formation of
conjugated dienes such as malondialdehyde, and vascular
leakage of protein. Affected cells respond by undergoing
programmed cell death (apoptosis) or necrosis. Neutrophil-
mediated damage to the lung mucosa removes an innate
barrier and allows exposure of capillaries and small ves-
sels to inflammatory mediators released in the lung and
bacteria within the exudate (figure 3).
3.3. Adhesion molecules of the acute inflammatory
response
Adhesion molecules that mediate passage of neutro-
phils into inflammatory sites initially involve relatively
unstable adherence between selectin molecules and their
glycoconjugate receptors (fucosylated oligosaccharide
molecules). L-selectin is expressed on neutrophils and
mediates neutrophil binding to endothelial cells. E- and
P-selectins are expressed mainly on endothelial cells and
mediate binding to neutrophil selectin receptors. Cytok-
Figure 3. Schematic representation of leukocytes, pro-inflammatory molecules, adhesions molecules, free radicals and enzymes integral to
leukocyte-mediated damage. Pro-inflammatory molecules include IL-1, TNF, IL-8 and MIP-1,2 (macrophage inflammatory protein).
These induce the initial adherence of leukocytes to endothelial cells via L and E selectin. The pro-inflammatory molecules also activate the
leukocytes and endothelial cells, resulting in the expression of adhesion molecules that mediate stable adherence: ICAM-1, PECAM-1, and
the 2 integrins. During transendothelial migration and within the perivascular stroma, free radicals such as nitric oxide (ONOO
–) from
macrophages and superoxide (O2
–) from NADPH oxidase of neutrophil granules can be released as well as degradative enzymes such as
elastase, cathespins, collagenase, and gelatinase.
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ines released during pneumonia activate neutrophils which
results in membrane surface expression of the 2 integrins
by neutrophils and immunoglobulin superfamily mol-
ecules such as ICAM-1 and PECAM-1 by endothelial cells
(figure 3).
The 2 integrins are glycoprotein heterodimers which
consist of one of four α subunits (CD11a, b, c or d) and a
constant2 subunit (CD18): CD11a/CD18 [LFA-1], CD11b/
CD18 [Mac-1], CD11c/CD18 [p150,95], and CD11d/
CD18. CD11b/CD18 is the predominant 2 integrin on
neutrophils. Neutrophil 2 integrin binds ICAM-1 mol-
ecules expressed on activated endothelial cells and this
mediates stable adherence between the neutrophils and
endothelial cells. During endothelial cell activation,
PECAM-1 production increases at the interendothelial cell
junctions and PECAM-1 mediates transendothelial cell
passage. In the extravascular stroma, fibroblasts can also
express ICAM-1 and are thought to bridge passage of
neutrophils from the vasculature to laminae in the base-
ment membrane of pulmonary epithelia. Respiratory epi-
thelial cells lining bronchi and bronchioles of cattle express
ICAM-1 [5], which mediates the final leg of neutrophil
infiltration into the airway space. In addition, recent work
suggests that neutrophils can adhere to VCAM-1 produced
by endothelial cells and extracellular matrix proteins such
as tenascin-C via 1 integrins (α91) [40]. Impaired expres-
sion of adhesion molecules can be lethal. For example,
mutations resulting in minimal expression of the 2 inte-
grins has been reported in humans beings, holstein cattle
and irish setter dogs resulting in severe, debilitating infec-
tions of the respiratory and alimentary tracts [41, 42].
Calf models of M. haemolytica in which neutrophil
adhesion molecules have been inhibited or eliminated
have been used to identify new therapeutic regimens [43,
44, 45]. It is thought that inhibition of neutrophil-mediated
pulmonary damage during early M. haemolytica may
have synergistic effects with antibiotic therapy. Such thera-
peutic regimens would potentially lessen both the
leukocyte- and microbial-induced aspects of pulmonary
damage.
Experimentally, inhibition of 2 integrin-mediated
adherence during M. haemolytica infection results in
reduced neutrophil infiltration into the pulmonary bronchi
and bronchioles [44], but does not appear to reduce
infiltration into the pulmonary alveoli [43]. This distribu-
tion of 2 integrin-mediated adherence in the bronchi and
bronchioles corresponds with the distribution of the 2
integrin receptor, ICAM-1, by bronchi and bronchiolar
epithelial cells. Evidently, the epithelium of these airways
and the extensive extravascular tissue matrix requires 2
integrin-mediated adherence. In contrast, neutrophil infil-
tration into alveoli during M. haemolytica pneumonia
does not require 2 integrins and alveolar epithelial cells
of cattle express relatively low amounts of the 2 integrin
receptor, ICAM-1 [5]. The reason for ability of neutrophils
to pass the alveolar wall independently of 2 integrins has
not been determined, nor has the alternative set of adhe-
sion molecules that mediate this passage. The 2 integrin-
independent passage is likely facilitated by the thin walls
of alveolar epithelial cells, the small amount of extracel-
lular matrix in alveolar septa, and fenestrations in the
basement membranes of the vascular endothelial cells and
alveolar epithelial cells.
Inhibition of selectin adherence by the oligosaccharide
mimetic, TBC1269, appears to reduce the extent of neu-
trophil infiltration and vascular leakage of protein during
M. haemolytica pneumonia in calves [45]. TBC1269
reduces adherence of all three (L, E, and P) selectins and
recent work suggests that TBC1269 increases the level of
apoptosis of infiltrating neutrophils [8]. The decrease in
vascular leakage of protein and infiltration of neutrophils
in combination with the increase in neutrophil apoptosis
during TBC1269 treatment of calves would suggest that
the compound may reduce damage of the pulmonary
tissue. The degree of membrane damage as measured by
conjugated diene formation is reduced by TBC1269 treat-
ment; however, the reduction was not significant statisti-
cally. Additional studies using higher numbers of animals
and older cattle may demonstrate a protective effect of at
least this one selectin inhibitor in M. haemolytica pneu-
monia. A possible synergistic role between TBC1269 or
other adhesion molecule inhibitors with antibiotics during
M. haemolytica pneumonia may be the basis for new
types of therapy.
3.4. Mast cells and substance P nerve fibers
Mast cells are located in the submucosa throughout the
respiratory tract, from the rostral nasal cavity to deep in the
pulmonary alveoli. The number of mast cells is limited in
neonatal ruminants and increases markedly with age. In
lungs of neonatal calves, there are 7.36 ± 0.8 mast cells/
mm2 [46]. These cells degranulate during M. haemolytica
infection and the number of stainable mast cells is reduced
to 2.8 ± 0.6 mast cells/mm2 by six hours after M.
haemolytica inoculation [46]. Sheep have a higher num-
ber of intrapulmonary mast cells; however, the number of
cells also decreases during acute M. haemolytica infec-
tion. Interestingly, the degranulation process of mast cells
occurs only in areas of active inflammation (associated
with dense infiltrates of neutrophils). Evidently in areas of
lung lacking neutrophilic infiltrates, mast cells are resistant
or not exposed to degranulation stimuli. If mast cells were
to degranulate throughout the entire lung tract during M.
haemolytica pneumonia, it would likely result in severe
edema, and broncho- and vasoconstriction in both infected
and noninfected areas. The limitation of mast cell degranu-
lation to the site of intense leukocyte infiltration during M.
haemolytica pneumonia contrasts sharply with the mast
cell activity in pulmonary hypersensitivity reactions and
asthma.
In addition to neutrophilic infiltration and IgE cross-
linking, mast cells can be stimulated to degranulate through
the release of substance P from autonomic nerve fibers.
These fibers are most densely arranged in the rostral
portion of the nasal septum, but are also present in the
trachea and lung. They may be important in initiation of
the acute inflammatory response during the very early
phases of M. haemolytica infection.
3.5. Pulmonary alveolar macrophages
PAMs are regulatory cells that control inflammatory,
immune and repair processes through the release of cytok-
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ines and other regulatory substances such eicosinoids and
platelet-activating factor. Circulating monocytes are the
precursors of PAMs, PIMs and dendritic cells of the
bronchus-associated lymphoid tissue. Monocyte adher-
ence is mediated by a broad set of adhesion molecules
including L, E, and P selectins, 1 integrins (VLA-4), 2
integrins, ICAM-1, PECAM-1, and VCAM-1. Because of
their location in lung, PAMs are exposed to M. haemolytica
or M. haemolytica constituents (such as LPS or LKT) almost
immediately after entrance of the bacteria into lung alveoli.
M. haemolytica polysaccharide reduces internalization
of M. haemolytica by PAMs [47] and M. haemolytica LPS
incites mRNA expression and protein production of TNF-α,
and IL-1 in PAMs [22]. M. haemolytica LPS also incites
IL-8 mRNA expression in a biphasic fashion with peaks at
1 to 2 and 16 to 24 hours after incubation [48]. PAMs
express tissue factor during M. haemolytica pneumonia,
and procoagulant activity of macrophages recovered from
pneumonic lung is increased 30-fold. The enhanced pro-
coagulant activity is exacerbated by the fact that macroph-
age and neutrophil profibrinolytic activity is reduced
23-fold [23]. This imbalance results not only in extensive
fibrin deposition, but also in retarded fibrin removal. As
indicated, antibodies to tissue factor greatly reduce fibrin
deposition [38].
3.6. Pulmonary intravascular macrophages
PIMs adhere tightly to endothelial cells of pulmonary
capillaries of several species including cattle, sheep, goats,
pigs, llama, deer, reindeer, horses and cats. PIMs function
to clear cellular and acellular material from the blood
during pneumonic conditions and release cytokines and
other regulatory factors similar to, but slightly different
from, PAMs. PIMs are present in other species (rabbits,
dogs, rats, mice, guinea pigs and human beings), but they
are few in number and difficult to discriminate from adher-
ent and activated monocytes. The numbers of PIMs in
ruminants are limited in neonates but increase with age
[49, 50, 51]. PIMs of neonatal calves appear to be more
differentiated than those of neonatal pigs. PIMs occupy
3.65% of the total capillary volume in cats [51], 15.3% of
the total capillary volume in sheep [50], and 6 and 25% of
the total capillary volume in neonatal and 30-day-old pigs
[49], respectively. PIMs are more active metabolically
than PAMs when stimulated by the calcium ionophore,
A23187 and produce eight arachidonic metabolites. The
major cyclooxygenase metabolite of A23187-stimulated
PIMs was hydroxyheptadecatrienoic acid and lipoxyge-
nase products including 5-HETE, 12-HETE, and LTB4 [52].
PIMs take up LPS and produce cytokines IL-1, TNF, and
PAF in addition to eicosinoids.
PIM adherence to pulmonary endothelial cells is medi-
ated by cell junctions termed ICAPs that are approximately
12 to 20 nm of electron-dense material that, in man, has
been demonstrated to consist of the 2 integrin, LFA-1
[53]. ICAPs have similarities to belt desmosomes of epi-
thelial cells (zona adherens, intermediate junctions), and
the ICAP distinguishes PIMs from adherent monocytes and
PAMs. Another characteristic ultrastructural feature of PIMs
is the cytoplasmic lamellar structures termed micropi-
nocytosis vermiformis.
PIMs from sheep and goats stain for alpha-naphthyl
butyrate esterase, secrete lysozyme, generate oxygen radi-
cals, release TNF and express Fc receptors [51]. PIMs are
highly phagocytic during M. haemolytica infection and
internalize neutrophils, platelets, and fibrin [19]. In swine,
PIM activity is reduced by viral infections (porcine repro-
ductive and respiratory syndrome virus) and mycotoxins
(Fusarium moniliforme) [54]. Little is known of the activity
of PIMs of cattle or sheep during M. haemolytica pneumo-
nia.
3.7. Lymphocytic inflammation
A detectable number of lymphocytes are sequestered in
the alveolar capillaries of calves with acute M. haemolytica
pneumonia [20]. However, most studies of lymphocyte
activity in the field of M. haemolytica pneumonia are
concerned with the responsiveness of these cells to vac-
cines. Live M. haemolytica vaccines, for example, induce
IFN-γ production and strong proliferation of lymphocytes
from mediastinal lymph node and, to a lesser degree,
superficial cervical lymph node. On the other hand, M.
haemolytica bacterins incite strongest proliferative
responses in cells and IFN-γ from superficial cervical
lymph node (near the vaccination site) [55].
4. Active immunity
Live M. haemolytica vaccines can enhance resistance
to infection; however, these vaccines can be associated
with local tissue reactions, transient anorexia, fever, and
even septicemia [56, 57]. Experimental vaccines with
partially purified M. haemolytica leukotoxin can induce
an antibody titer [56], but the effectiveness in preventing
pneumonia has not been fully determined. Despite some
improvement in managerial practices, vaccines and clini-
cal therapies, M. haemolytica pneumonia remains a wide-
spread problem and strategies to enhance host resistance
to colonization and pneumonia by M. haemolytica are
needed.
Non-vaccinated cattle infected with M. haemolytica
develop serum IgM titers by five days postinfection and
IgG titers by seven days [58]. Commercial vaccines in the
United States induce a degree of protection in most trials.
Vaccines are typically killed bacterins or modified live
products with or without LKT. In one study, both a bacterin-
toxoid (OneShot, Pfizer) and a modified live vaccine (Once
PMH, Bayer Corp.) induced protection against challenge;
however, the bacterin-toxoid provided the greatest degree
of protection. The oil adjuvant in the bacterin-toxoid may
have contributed to the difference between the two vac-
cines, since oil adjuvants are more effective than alumi-
num hydroxide for reducing lung lesions upon challenge
[57] and for stimulating antibody response. Adjuvants
such as muramyl dipeptide also enhance vaccine protec-
tion [59]. Non-living M. haemolytica vaccines (OneShot
[Pfizer], Presponse HP/tK, and Septimure PHK) induce
antibody titers to whole cell M. haemolytica between
seven and 14 days after vaccination, but only two of the
vaccines (OneShot ant Presponse) induced antibody titers
to LKT. Upon revaccination, cattle generated an anamnes-
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tic response. Antibodies were increased for up to 84 days
after vaccination or revaccination [60].
Delivery is an important factor of vaccination. Cattle
receiving intranasal M. haemolytica vaccines develop anti-
bodies in nasal secretions and bronchoalveolar lavage
fluid. In contrast, cattle receiving vaccine at the tracheal
bifurcation produce antibodies in the bronchoalveolar
lavage fluid, but not nasal secretions [61].
Several laboratories have utilized LKT as an antigenic
molecule for vaccination. Reductions in the activity or
production of LKT would reduce the degree of LKT-induced
leukocyte damage and apoptosis. LKT with an aluminum
adjuvant stimulated a humoral response to LKT and only a
low response to formalized M. haemolytica or to outer
membrane proteins of M. haemolytica [56]. An LKT-IL-2
molecular chimera did not increase antibody production;
however, it may increase lymphocyte proliferation [62].
Outer membrane proteins (OMPs) of M. haemolytica
also have potential to be important antigens for acquired
immunity. Antibodies to M. haemolytica OMPs are asso-
ciated with resistance to M. haemolytica challenge in
cattle. Many of the OMPs are exposed on the surface of M.
haemolytica S1 strains and, thereby, are readily recog-
nized by leukocytes and circulating antibodies [63]. Loss
of three membrane lipoproteins in an M. haemolytica
mutant resulted in enhanced susceptibility to complement-
mediated killing [64]. One lipoprotein, PlpE has sequence
homology to OmlA of Actinobacillus pleuropneumoniae,
and antibodies to PlpE enhance killing of M. haemolytica
[65]. Four lipoproteins (Plp 1-4) that are 30 kDa or greater
have been characterized by Nardini, Mellors and Lo [66].
The lipid portion of these molecules may be responsible
for the immunogenicity. One of the four, Plp4, is a 31-kDa
lipoprotein with regions of homology with antigens from
Haemophilus somnus, Neiseseria meningitidis, and the
OmpA family.
4.1. Immune complex-mediated vascular change
Immune complexes may contribute to the pathology of
M. haemolytica pneumonia. Immune complexes com-
posed of IgG complexed with OMPs of M. haemolytica
and complement fragments are present in the lungs of a
mouse model [67]. Other work has demonstrated an
Arthus-like reaction in rabbits first vaccinated with M.
haemolytica bacterin, then receiving M. haemolytica LPS
intratracheally [68]. The lungs of the rabbits had extensive
vascular edema and neutrophilic infiltration with features
similar to those of M. haemolytica pneumonia.
5. Chronic pneumonia
The gross and microscopic changes that occur follow-
ing the initial acute necrotizing pneumonic episode of M.
haemolytica pneumonia have been recognized for many
years but infrequently studied. Necrotic areas are infil-
trated by macrophages and fibroblasts and become
encased in capsules of fibrous trabeculae. In time, these
regions become remodeled into a granulomatous area. In
chronic lung injuries in human patients with bacterial
pneumonia, mast cell numbers increase. The numbers of
mast cells in chronic bovine pulmonary pasteurellosis
have not been determined. Potentially, therapies aimed to
remodel granulomas and fibrous connective tissue could
be developed. These regions may then become sites for
new bronchiole and alveolar units to form.
Although the number of mast cells is greatly reduced
following acute M. haemolytica infection, there is a sig-
nificant increase in mast cells at 15 days following experi-
mental M. haemolytica infection in sheep (R. Ramierez-
Romereo, personal communication). This increase is
present only in the areas of lung in which there was an
intense acute inflammatory response. The increase in mast
cells in these areas may predispose the lung to reinfection.
Alternatively, the mast cells may contribute to the hyper-
sensitivity type of reactions that can be seen with viruses
such respiratory syncytial virus or with allergic responses
such as asthma.
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